IMTX vs NVCR
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
IMTX exhibits severe fundamental distress, highlighted by a Piotroski F-Score of 1/9, indicating critical weakness in financial health and operational efficiency. While the company maintains an exceptionally strong liquidity position (Current Ratio of 11.72) and low debt, these are overshadowed by a catastrophic 64.90% year-over-year decline in revenue and deeply negative gross margins (-280.87%). The stock currently trades at a speculative premium with a Price/Sales ratio of 28.98 despite shrinking top-line growth. Any potential upside is driven by analyst price targets ($18.75) rather than current financial performance.
NVCR exhibits significant financial fragility with a weak Piotroski F-Score of 3/9 and a complete lack of positive deterministic value markers (Graham/Intrinsic). While the company maintains a strong gross margin of 74.8% and healthy short-term liquidity (Current Ratio 2.90), these are offset by persistent negative profit margins and a catastrophic 5-year price decline of 93.7%. The disconnect between bullish analyst targets ($25.07) and aggressive insider selling by the CFO and COO suggests a lack of internal confidence in near-term catalysts.
Compare Another Pair
Related Comparisons
IMTX vs NVCR: Head-to-Head Comparison
This page compares Immatics N.V. (IMTX) and NovoCure Limited (NVCR) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.